Русский
The effectiveness of Alloferon in the complex therapy of chronic recurrent papillomavirus cystitis
DOI: https://dx.doi.org/10.18565/urology.2021.4.35-40
К.S. Ibishev, D.V. Krakhotkin, V. K. Mamedov, A.I. Palenyy
Rostov State Medical University, Rostov-on-Don, Russia
Introduction: Chronic recurrent cystitis (CRC) for women is one of the most pressing and unresolved problems of modern urology.
Purpose of the research: To study the effectiveness of Alloferon (Allokin-alpha) in the complex therapy of chronic reactive papillomavirus cystitis.
Materials and methods: 46 patients with CRC PV-etiology were examined, which, depending on the therapy, were randomized into two groups. Patients of group I (n=22) received combination therapy supplemented with Alloferon, which was injected subcutaneously every 1 day, for a course of 6 injections. Group II (control) (n=24) – combination therapy without study drug. The effectiveness of treatment was assessed immediately after treatment, after 1, 3, 6 months, from the beginning of therapy.
Results: When analyzing the results of treatment, a significant improvement in clinical indicators was noted in patients of group I who received complex therapy, which included Alloferon, after 1 month from the start of treatment, there was a significant decrease in pain symptoms and LUTS, an improvement in the quality of life of patients compared with group II. When evaluating the dynamics of laboratory data, in the general analysis of urine, a significant decrease in the level of leukocytes and erythrocytes in the general analysis of urine was noted. In addition, the analysis of the data of cytological examination of urine revealed a decrease in the specific sign of papillomavirus lesions of the bladder - coylocytosis: after 6 months. From the start of therapy, no coylocytes were detected in group I, while in group II, coylocytes in urine were detected in 8 (33.3%) patients.
Conclusions: The use of Alloferon (Allokin-alpha) in the complex therapy of patients with CRC PV etiology improved clinical and laboratory parameters after 1 month. after starting therapy, while the undoubted advantage of the drug is a faster reduction in pain, which significantly increased the quality of life.
Purpose of the research: To study the effectiveness of Alloferon (Allokin-alpha) in the complex therapy of chronic reactive papillomavirus cystitis.
Materials and methods: 46 patients with CRC PV-etiology were examined, which, depending on the therapy, were randomized into two groups. Patients of group I (n=22) received combination therapy supplemented with Alloferon, which was injected subcutaneously every 1 day, for a course of 6 injections. Group II (control) (n=24) – combination therapy without study drug. The effectiveness of treatment was assessed immediately after treatment, after 1, 3, 6 months, from the beginning of therapy.
Results: When analyzing the results of treatment, a significant improvement in clinical indicators was noted in patients of group I who received complex therapy, which included Alloferon, after 1 month from the start of treatment, there was a significant decrease in pain symptoms and LUTS, an improvement in the quality of life of patients compared with group II. When evaluating the dynamics of laboratory data, in the general analysis of urine, a significant decrease in the level of leukocytes and erythrocytes in the general analysis of urine was noted. In addition, the analysis of the data of cytological examination of urine revealed a decrease in the specific sign of papillomavirus lesions of the bladder - coylocytosis: after 6 months. From the start of therapy, no coylocytes were detected in group I, while in group II, coylocytes in urine were detected in 8 (33.3%) patients.
Conclusions: The use of Alloferon (Allokin-alpha) in the complex therapy of patients with CRC PV etiology improved clinical and laboratory parameters after 1 month. after starting therapy, while the undoubted advantage of the drug is a faster reduction in pain, which significantly increased the quality of life.
About the Autors
Corresponding author: K.S. Ibishev – Doctor of Medical Sciences, Professor of the Department of Urology and Human Reproductive Health (with a course of pediatric urology and andrology), Rostov State Medical University, Ministry of Health of Russia, Rostov-on-Don, Russia; e-mail: ibishev22@mail.ru
Similar Articles
